Does the media prefer NGNE or NAMS?

In the previous week, NewAmsterdam Pharma had 12 more articles in the media than Neurogene. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 6 mentions for Neurogene. Neurogene's average media sentiment score of 1.13 beat NewAmsterdam Pharma's score of 0.44 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, NGNE or QURE?

Neurogene has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neurogene $930K 763.39 -$90.35M -$5.03 N/A uniQure $16.10M 191.78 -$198.97M -$4.01 N/A

Is NGNE or QURE more profitable?

Neurogene has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Neurogene's return on equity of -45.10% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -45.10% -41.00% uniQure -1,350.73% -111.96% -29.01%

Does the media favor NGNE or QURE?

In the previous week, Neurogene had 3 more articles in the media than uniQure. MarketBeat recorded 6 mentions for Neurogene and 3 mentions for uniQure. Neurogene's average media sentiment score of 1.13 beat uniQure's score of 0.92 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ZLAB or NGNE?

Neurogene has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 5.97 -$175.54M -$1.71 N/A Neurogene $930K 763.39 -$90.35M -$5.03 N/A

Is ZLAB or NGNE more profitable?

Neurogene has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -41.86% -27.43% -16.72% Neurogene N/A -45.10% -41.00%

Does the media favor ZLAB or NGNE?

In the previous week, Neurogene had 4 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Neurogene and 2 mentions for Zai Lab. Neurogene's average media sentiment score of 1.13 beat Zai Lab's score of 0.71 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is SLS or NGNE more profitable?

SELLAS Life Sciences Group's return on equity of -35.91% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -35.91% -33.34% Neurogene N/A -45.10% -41.00%

Does the media prefer SLS or NGNE?

In the previous week, Neurogene had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Neurogene and 5 mentions for SELLAS Life Sciences Group. Neurogene's average media sentiment score of 1.13 beat SELLAS Life Sciences Group's score of 0.80 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NRIX or NGNE?

In the previous week, Neurogene had 3 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Neurogene and 3 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.32 beat Neurogene's score of 1.13 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Neurogene (NGNE) Competitors

$35.48 -0.64 (-1.77%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$35.52 +0.05 (+0.13%)

As of 09/11/2026 07:30 PM Eastern

Compare

NGNE vs. NAMS, QURE, ZLAB, SLS, and NRIX

Should you buy Neurogene stock or one of its competitors? Neurogene's main competitors and comparable companies include NewAmsterdam Pharma (NAMS), uniQure (QURE), Zai Lab (ZLAB), SELLAS Life Sciences Group (SLS), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Neurogene compare to NewAmsterdam Pharma?

Neurogene (NASDAQ:NGNE) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Neurogene has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	763.39	-$90.35M	-$5.03	N/A
NewAmsterdam Pharma	$22.50M	121.13	-$203.82M	-$2.16	N/A

Neurogene presently has a consensus price target of $83.67, indicating a potential upside of 135.81%. NewAmsterdam Pharma has a consensus price target of $49.73, indicating a potential upside of 118.10%. Given Neurogene's higher possible upside, analysts plainly believe Neurogene is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Neurogene has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

In the previous week, NewAmsterdam Pharma had 12 more articles in the media than Neurogene. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 6 mentions for Neurogene. Neurogene's average media sentiment score of 1.13 beat NewAmsterdam Pharma's score of 0.44 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Neurogene has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

Summary

NewAmsterdam Pharma beats Neurogene on 9 of the 16 factors compared between the two stocks.

How does Neurogene compare to uniQure?

Neurogene (NASDAQ:NGNE) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

52.4% of Neurogene shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 11.7% of Neurogene shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Neurogene has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, uniQure has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Neurogene currently has a consensus price target of $83.67, indicating a potential upside of 135.81%. uniQure has a consensus price target of $65.00, indicating a potential upside of 46.03%. Given Neurogene's stronger consensus rating and higher probable upside, analysts plainly believe Neurogene is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

In the previous week, Neurogene had 3 more articles in the media than uniQure. MarketBeat recorded 6 mentions for Neurogene and 3 mentions for uniQure. Neurogene's average media sentiment score of 1.13 beat uniQure's score of 0.92 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurogene has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Neurogene's return on equity of -45.10% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
uniQure	-1,350.73%	-111.96%	-29.01%

Neurogene has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	763.39	-$90.35M	-$5.03	N/A
uniQure	$16.10M	191.78	-$198.97M	-$4.01	N/A

Summary

Neurogene beats uniQure on 12 of the 17 factors compared between the two stocks.

How does Neurogene compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Neurogene (NASDAQ:NGNE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Neurogene has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	5.97	-$175.54M	-$1.71	N/A
Neurogene	$930K	763.39	-$90.35M	-$5.03	N/A

In the previous week, Neurogene had 4 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Neurogene and 2 mentions for Zai Lab. Neurogene's average media sentiment score of 1.13 beat Zai Lab's score of 0.71 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zai Lab has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Neurogene has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Neurogene	N/A	-45.10%	-41.00%

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by insiders. Comparatively, 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Zai Lab currently has a consensus target price of $37.25, suggesting a potential upside of 54.31%. Neurogene has a consensus target price of $83.67, suggesting a potential upside of 135.81%. Given Neurogene's stronger consensus rating and higher probable upside, analysts plainly believe Neurogene is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Neurogene beats Zai Lab on 11 of the 15 factors compared between the two stocks.

How does Neurogene compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Neurogene (NASDAQ:NGNE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 11.7% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Neurogene had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Neurogene and 5 mentions for SELLAS Life Sciences Group. Neurogene's average media sentiment score of 1.13 beat SELLAS Life Sciences Group's score of 0.80 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group has a beta of 2.52, suggesting that its share price is 152% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

SELLAS Life Sciences Group currently has a consensus target price of $10.00, indicating a potential downside of 13.42%. Neurogene has a consensus target price of $83.67, indicating a potential upside of 135.81%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

SELLAS Life Sciences Group's return on equity of -35.91% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Neurogene	N/A	-45.10%	-41.00%

SELLAS Life Sciences Group has higher earnings, but lower revenue than Neurogene. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Neurogene	$930K	763.39	-$90.35M	-$5.03	N/A

Summary

Neurogene beats SELLAS Life Sciences Group on 10 of the 15 factors compared between the two stocks.

How does Neurogene compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Neurogene (NASDAQ:NGNE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

In the previous week, Neurogene had 3 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Neurogene and 3 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.32 beat Neurogene's score of 1.13 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nurix Therapeutics presently has a consensus price target of $34.21, suggesting a potential upside of 36.31%. Neurogene has a consensus price target of $83.67, suggesting a potential upside of 135.81%. Given Neurogene's stronger consensus rating and higher probable upside, analysts clearly believe Neurogene is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Neurogene has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Neurogene's return on equity of -45.10% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Neurogene	N/A	-45.10%	-41.00%

52.4% of Neurogene shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by insiders. Comparatively, 11.7% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nurix Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

Neurogene has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	31.02	-$264.46M	-$3.45	N/A
Neurogene	$930K	763.39	-$90.35M	-$5.03	N/A

Summary

Neurogene beats Nurix Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Neurogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGNE vs. The Competition

Export

Metric	Neurogene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$710M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-7.05	14.18	274.94	25.33
Price / Sales	763.39	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	2.07	15.12	10.33	6.21
Net Income	-$90.35M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-8.08%	-4.34%	-3.32%	-2.35%
1 Month Performance	-0.42%	0.54%	-0.53%	-3.23%
1 Year Performance	86.74%	40.74%	23.51%	8.79%

Neurogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGNE Neurogene	2.5727 of 5 stars	$35.48 -1.8%	$83.67 +135.8%	+86.7%	$710M	$930K	N/A	131	News Coverage Positive News
NAMS NewAmsterdam Pharma	2.8688 of 5 stars	$25.26 -0.6%	$49.73 +96.9%	-5.7%	$3.06B	$22.50M	N/A	4	News Coverage Analyst Forecast
QURE uniQure	3.5429 of 5 stars	$44.06 -1.0%	$65.00 +47.5%	+169.9%	$3.05B	$16.10M	N/A	500	Gap Down
ZLAB Zai Lab	2.3038 of 5 stars	$25.68 -2.1%	$37.25 +45.0%	-26.4%	$2.92B	$449.61M	N/A	1,784
SLS SELLAS Life Sciences Group	0.4916 of 5 stars	$14.06 +1.4%	$10.00 -28.9%	+524.3%	$2.86B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGNE) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurogene (NGNE) Competitors

NGNE vs. NAMS, QURE, ZLAB, SLS, and NRIX

How does Neurogene compare to NewAmsterdam Pharma?

Summary

How does Neurogene compare to uniQure?

Summary

How does Neurogene compare to Zai Lab?

Summary

How does Neurogene compare to SELLAS Life Sciences Group?

Summary

How does Neurogene compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurogene (NGNE) Competitors

NGNE vs. NAMS, QURE, ZLAB, SLS, and NRIX

How does Neurogene compare to NewAmsterdam Pharma?

Which has higher valuation and earnings, NGNE or NAMS?

Do analysts prefer NGNE or NAMS?

Which has more volatility & risk, NGNE or NAMS?

Does the media prefer NGNE or NAMS?

Do insiders & institutionals believe in NGNE or NAMS?

Is NGNE or NAMS more profitable?

Summary

How does Neurogene compare to uniQure?

Do insiders and institutionals have more ownership in NGNE or QURE?

Which has more risk & volatility, NGNE or QURE?

Do analysts recommend NGNE or QURE?

Does the media favor NGNE or QURE?

Is NGNE or QURE more profitable?

Which has preferable earnings and valuation, NGNE or QURE?

Summary

How does Neurogene compare to Zai Lab?

Which has stronger valuation and earnings, ZLAB or NGNE?

Does the media favor ZLAB or NGNE?

Which has more risk & volatility, ZLAB or NGNE?

Is ZLAB or NGNE more profitable?

Do insiders & institutionals hold more shares of ZLAB or NGNE?

Do analysts prefer ZLAB or NGNE?

Summary

How does Neurogene compare to SELLAS Life Sciences Group?

Do institutionals & insiders believe in SLS or NGNE?

Does the media prefer SLS or NGNE?

Which has more volatility & risk, SLS or NGNE?

Do analysts recommend SLS or NGNE?

Is SLS or NGNE more profitable?

Which has better earnings & valuation, SLS or NGNE?

Summary

How does Neurogene compare to Nurix Therapeutics?

Does the media prefer NRIX or NGNE?

Do analysts rate NRIX or NGNE?

Is NRIX or NGNE more profitable?

Do institutionals & insiders have more ownership in NRIX or NGNE?

Which has more risk and volatility, NRIX or NGNE?

Which has higher valuation and earnings, NRIX or NGNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools